Clearstone Central Laboratories Debuts
MDS Pharma Services' Central Labs business will now be known as Clearstone Central Laboratories, and becomes part of Czura Thornton's Life Sciences Group.
In a joint statement, Czura Thornton's founders Tony Czura and Nick Thornton said: "We are delighted to augment our Life Sciences Group with Clearstone Central Laboratories and the deep expertise of the people there. We intend to maintain the integrity of the operational teams and continue to invest in strengthening the company's focus on exceptional client service. Combined with our renewed focus on the consistent delivery of high quality service, flexibility and responsiveness that private ownership allows, we look forward to expanding Clearstone's market reach." Czura Thornton also owns the CRO Chiltern, as well as other interests in life sciences, international trade, property and automtive sectors. This article discusses Czura Thornton's plans for Clearstone moving forward.
Clearstone Central Laboratories is a large private Global Central Laboratory companies solely focused on clinical research and cardiac services. Through a network of wholly owned CAP certified laboratories, Clearstone offers central laboratory services in the Americas, Europe and Asia, which are all equivalently equipped and harmonized to provide consistent, dependable results across programs, study phases and geographies. In addition, Clearstone leverages information technology tools aligned with value add project management principles for managing global clinical trials. Each of its laboratories utilizes the company's centralized APOLLO-CLPM™ (Central Laboratory Protocol Manager) enabling Clearstone project management teams with real-time visibility to component and test level data. Viq Pervaaz, Vice President of Global Project Management commented, "We facilitate our strong project management and data management teams with innovative technology solutions and an advanced web based protocol management system to meet the needs of our clients."
Clearstone Central Laboratories has over 600 employees and facilities in Paris, Hamburg, Toronto, New Jersey, *Beijing and Singapore.
For further information see www.clearstonelabs.com.
*The acquisition of the China business is pending subject to receipt of required Chinese governmental approvals.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
